François Martelet
Chief Executive Officer bei SCANDION ONCOLOGY A/S
Profil
François R.
Martelet currently works at Scandion Oncology A, as Chief Executive Officer from 2023, Novigenix SA, as Independent Director from 2019, and Ennovance Capital LLC, as Senior Advisor.
Dr. Martelet also formerly worked at AVAX Technologies, Inc., as President & Chief Executive Officer from 2007 to 2009, Topotarget A, as Chief Executive Officer & Head-Investor Relations from 2010 to 2012, Vivesto AB, as Chief Executive Officer from 2020 to 2022, NetScientific Plc, as Chief Executive Officer & Executive Director from 2015 to 2019, Vortex BioSciences, Inc., as Chairman, Glycotest, Inc., as Chairman, ProAxsis Ltd., as Chairman, Merck & Co., Inc., as Vice President & Global Franchise Head-Oncology from 2005 to 2006, Novartis AG, as Head-Regional Pharma from 2003 to 2005, and Stallergenes SA, as Senior Vice President-International Operations.
Dr. Martelet received his Masters Business Admin degree and doctorate degree from the University of Dijon, undergraduate degree from Université de Paris 5 René Descartes, and graduate degree from Burgundy School of Business.
Aktive Positionen von François Martelet
| Unternehmen | Position | Beginn |
|---|---|---|
| SCANDION ONCOLOGY A/S | Chief Executive Officer | 02.01.2023 |
Ennovance Capital LLC
 Ennovance Capital LLC Investment ManagersFinance Ennovance Capital LLC (Ennovance Capital) is a private equity firm founded in 2008. The firm is headquartered in Philadelphia, Pennsylvania. | Corporate Officer/Principal | 27.01.2010 |
Novigenix SA
 Novigenix SA Medical SpecialtiesHealth Technology Novigenix SA develops molecular diagnostics for cancer. The firm specializes in new generation liquid biopsy tests for early detection of cancer and precision medicine. The company was founded by Sahar Hosseinian in 2014 and is headquartered in Epalinges, Switzerland. | Director/Board Member | 18.06.2019 |
Ehemalige bekannte Positionen von François Martelet
| Unternehmen | Position | Ende |
|---|---|---|
| VIVESTO AB | Chief Executive Officer | 21.07.2022 |
| NETSCIENTIFIC PLC | Chief Executive Officer | 30.04.2019 |
| TOPOTARGET A/S | Chief Executive Officer | 30.08.2012 |
| AVAX TECHNOLOGIES, INC. | Chief Executive Officer | 01.01.2009 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01.12.2006 |
Ausbildung von François Martelet
| University of Dijon | Doctorate Degree |
| Burgundy School of Business | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| AVAX TECHNOLOGIES, INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| VIVESTO AB | Health Technology |
| NETSCIENTIFIC PLC | Health Technology |
| SCANDION ONCOLOGY A/S | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Stallergenes SA
 Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
Topotarget A/S
 Topotarget A/S Pharmaceuticals: MajorHealth Technology Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark. | Health Technology |
Ennovance Capital LLC
Ennovance Capital LLC Investment ManagersFinance Ennovance Capital LLC (Ennovance Capital) is a private equity firm founded in 2008. The firm is headquartered in Philadelphia, Pennsylvania. | Finance |
| Université de Paris 5 René Descartes | Consumer Services |
Novigenix SA
Novigenix SA Medical SpecialtiesHealth Technology Novigenix SA develops molecular diagnostics for cancer. The firm specializes in new generation liquid biopsy tests for early detection of cancer and precision medicine. The company was founded by Sahar Hosseinian in 2014 and is headquartered in Epalinges, Switzerland. | Health Technology |
Vortex BioSciences, Inc.
 Vortex BioSciences, Inc. Medical SpecialtiesHealth Technology Vortex BioSciences, Inc. provides a solution for routine isolation and purification of Circulating Tumor Cells (CTC). It offers VTX-1, an automated system that isolates intact CTCs directly from whole blood with high recovery and high purity. The company was founded by Dino Di Carlo and Elodie Sollier and is headquartered in Pleasanton, CA. | Health Technology |
Glycotest, Inc.
 Glycotest, Inc. Electronic Equipment/InstrumentsElectronic Technology Glycotest, Inc. develops diagnostic markers for liver disease diagnosis. It offers disease signal chemistry (glycoprotein fucosylation) present in liver cancers and fibrosis-cirrhosis but absent in healthy individuals. The company was founded in 2012 and is headquartered in New York, NY. | Electronic Technology |
ProAxsis Ltd.
 ProAxsis Ltd. Pharmaceuticals: MajorHealth Technology ProAxsis Ltd. manufactures and markets pharmaceutical products . It offers clinical research and research and development services. The company was founded by Lorraine Martin and Brian Walker in August 2013 and is headquartered in Belfast, the United Kingdom. | Health Technology |
